Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
04:12pm, Thursday, 26'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announc
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?
10:46am, Thursday, 26'th Sep 2024
Here is how ChromaDex (CDXC) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
08:32am, Friday, 20'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CFO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appoi
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
08:32am, Tuesday, 10'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
08:34am, Monday, 09'th Sep 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #25thAnniversary--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
08:34am, Friday, 23'rd Aug 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #BioScience--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced to
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
07:25pm, Wednesday, 07'th Aug 2024
ChromaDex (CDXC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
08:34am, Monday, 22'nd Jul 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
08:34am, Tuesday, 16'th Jul 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces Wel
ChromaDex: Looking To Take The Big Step Into Pharma
12:20pm, Wednesday, 26'th Jun 2024
ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC ca
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II cl
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveil
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
10:45am, Monday, 10'th Jun 2024
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that the
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
08:32am, Tuesday, 04'th Jun 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it w
